Comparative Pharmacology
Head-to-head clinical analysis: LOMOTIL versus LOPERAMIDE HYDROCHLORIDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: LOMOTIL versus LOPERAMIDE HYDROCHLORIDE.
LOMOTIL vs LOPERAMIDE HYDROCHLORIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Diphenoxylate is a meperidine congener that acts as an opioid receptor agonist, inhibiting gastrointestinal motility and prolonging transit time; atropine is added to discourage abuse at high doses.
Loperamide binds to µ-opioid receptors in the intestinal wall, reducing propulsive peristalsis and increasing intestinal transit time. It also inhibits calcium-calmodulin-dependent pathways, decreasing electrolyte and water secretion, and enhances anal sphincter tone.
Adults: 2 tablets (2.5 mg diphenoxylate/0.025 mg atropine) orally four times daily until control of diarrhea is achieved; maintenance dose is 2 tablets once or twice daily. Maximum dose: 8 tablets (20 mg diphenoxylate) per day.
4 mg orally initially, followed by 2 mg after each unformed stool; maximum 16 mg per day. For chronic diarrhea, 4 mg orally once, then 2 mg after each unformed stool until diarrhea controlled; typical maintenance 4-8 mg daily in divided doses. Traveler's diarrhea: 4 mg initially, then 2 mg after each loose stool; maximum 8 mg per day for up to 2 days.
None Documented
None Documented
Diphenoxylate: 2.5-3.5 hours; Difenoxin (active metabolite): 12-24 hours. Clinically, antidiarrheal effect is prolonged due to metabolite accumulation.
Terminal elimination half-life is 9-14 hours (mean 10.8 hours) in adults; may be prolonged in hepatic impairment.
Primarily renal (50-70% as metabolites, <5% unchanged) and fecal (30-50% via biliary excretion).
Primarily fecal (30-40% as unchanged drug, 50-60% as metabolites); renal excretion accounts for <5% of unchanged drug and ~10% of metabolites.
Category C
Category A/B
Antidiarrheal
Antidiarrheal